Initiate a Phase 2/3 program for ACP-204 in Alzheimer’s disease psychosis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- November 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“commence a seamless Phase 2 and 3 program to study ACP-204 in Alzheimer’s disease psychosis”
What we found
Evidence strength A What the grades mean
Acadia Pharmaceuticals initiated its seamless Phase 2/3 program for ACP-204 in Alzheimer’s disease psychosis in November 2023, meeting the fourth-quarter 2023 deadline.
-
A Acadia Pharmaceuticals Inc. 8-K filed 2024-02-27
“In the fourth quarter we significantly advanced our pipeline with the initiation of a Phase 3 trial of ACP-101 in Prader-Willi syndrome, as well as our seamless Phase 2 / Phase 3 program for ACP-204” ✓ confirmed on the page
-
A Acadia Pharmaceuticals Inc. 10-K filed 2024-02-28
“In November 2023, we initiated a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with ADP.” ✓ confirmed on the page
-
A Acadia Pharmaceuticals Inc. 10-K filed 2024-02-28
“The Phase 2 study is part of a seamless Phase 2 / Phase 3 program that includes three studies” ✓ confirmed on the page
Market reaction: the shares moved -10.7% against the S&P 500 over the three sessions around the disclosure (26 Feb 2024 to 29 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 2 Aug 2023
Deadline 31 Dec 2023 (“fourth quarter of this year”)
-
Version 2 · stated 2 Nov 2023
Deadline 31 Dec 2023 (“in the fourth quarter of 2023”) · wording expected
“The Company plans to initiate a Phase 2 study of ACP-204 as a potential treatment for Alzheimer’s disease psychosis in the fourth quarter of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Phase 2/3 program for ACP-204
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ACAD-002585 · Corrections policy